| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 30th September 2020 | Charles B O'Keeffe | 7,000 | Open or private purchase | $2.99 | $20,930.00 |
| 30th September 2020 | Patrick J Mcenany | 15,000 | Open or private purchase | $2.97 | $44,550.00 |
| 5th December 2019 | Gary Ingenito | 150,000 | Open or private sale | $4.82 | $723,150.00 |
| 4th December 2019 | Gary Ingenito | 150,000 | Exercise of derivative | $2.53 | $379,500.00 |
| 27th November 2019 | Gary Ingenito | 100,000 | Exercise of derivative | $1.13 | $113,000.00 |
| 27th November 2019 | Gary Ingenito | 100,000 | Open or private sale | $4.66 | $466,000.00 |
| 21st November 2019 | Gary Ingenito | 100,000 | Open or private sale | $4.50 | $449,800.00 |
| 20th November 2019 | Gary Ingenito | 100,000 | Exercise of derivative | $0.79 | $79,000.00 |
| 11th October 2019 | Charles B O'Keeffe | 10,000 | Open or private purchase | $4.70 | $46,950.00 |
| 3rd October 2019 | Patrick J Mcenany | 10,000 | Open or private purchase | $4.89 | $48,900.00 |
Catalyst Pharmaceuticals
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Catalyst Pharmaceuticals is a biopharmaceutical company. The company was founded Huckel E. Hubert in January 2002 and is headquartered in Coral Gables, FL. It is developing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases.
Ticker: CPRX
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1369568
Employees: 76
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $115 M (0%)
Inventory, Net: $2 M (-6%)
Assets, Current: $131 M (17%)
Property, Plant and Equipment, Net: $168 Th (-20%)
Assets: $131 M (16%)
Accounts Payable, Current: $6 M (40%)
Accrued Liabilities, Current: $14 M (0%)
Liabilities, Current: $20 M (-16%)
Liabilities: $20 M (-18%)
Common Stock, Value, Issued: $103 Th (0%)
Common Stock, Shares, Issued: $103 M (0%)
Retained Earnings (Accumulated Deficit): $108 M (-15%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $1 Th (-87%)
Stockholders' Equity (Parent): $111 M (0%)
Liabilities and Equity: $131 M (16%)
Revenue: $30 M (-49%)
Cost of Revenue: $4 M (-50%)
Research and Development: $4 M (-49%)
Operating Income/Loss: $10 M (-50%)
Provision for income taxes: $613 Th (-49%)
EPS (basic): $0.09 (-55%)
EPS (diluted): $0.09 (-52%)
News
Behind real estate’s surprise 2020 boom and what comes next
24th October 2020
US judge will not reverse decision on WeChat app store ban
23rd October 2020